If you are a blood cancer patient, survivor, caregiver in the United States, or know someone who is, The Leukemia & Lymphoma Society (LLS) needs your help with a research initiative aimed at learning more about COVID-19 and blood cancer patients. We invite patients and survivors to sign up for The LLS National Patient Registry to help shape discoveries that can improve the quality of life and care for people living with blood cancers.
About the Registry
The LLS National Patient Registry gathers and studies information from patients diagnosed with blood cancers (past or present) to help researchers better understand outcomes and tailor treatments.
The Registry is currently focused on answering important questions about blood cancer patients and COVID-19. This is a unique opportunity for blood cancer patients to join LLS to increase scientific knowledge about how COVID-19 and COVID-19 vaccines affect them.
What you need to know:
-Patients and survivors in the United States are invited to join whether or not you have tested positive for COVID-19 and whether or not you plan to be vaccinated.
-Joining takes less than 10 minutes and can be done on your phone or computer.
-Your information will be kept anonymous. The Registry abides by HIPAA guidelines to ensure any information you share remains confidential and secure.
-There is no cost to you to join the Registry.
We encourage all blood cancer patients and survivors to become “citizen scientists” by joining the Registry today. Together, we will change the future of blood cancer care.
Monday to Friday, 9 a.m. to 9 p.m. ET
Email Us: Click Here
All email messages are answered within one business day
Leave a message 24/7 and we’ll call back. 844-696-7228 to use the automated response system 24 hours a day, seven days a week.
|Access Date||Quiz Result||Score||Actions|
Please log in first before proceeding to the Sessions page
Please make sure the password is typed in ALL CAPS and includes the exclamation point. Enter the email address that you used to register for the conference.